SAKAR.NS
Sakar Healthcare Limited [SAKAR.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SAKAR.NS Stock Summary
Top SAKAR.NS Correlated Resources
SAKAR.NS
Top 10 Correlated ETFs
SAKAR.NS
Top 10 Correlated Stocks
SAKAR.NS
In the News
SAKAR.NS Financial details
Company Rating
Buy
Market Cap
8.04B
Income
144.11M
Revenue
1.47B
Book val./share
109.49
Cash/share
0.15
Dividend
-
Dividend %
-
Employees
297
Optionable
No
Shortable
Yes
Earnings
08 Feb 2024
P/E
56.61
Forward P/E
-
PEG
-19.36
P/S
5.47
P/B
3.44
P/C
2539
P/FCF
-
Quick Ratio
0.44
Current Ratio
1.23
Debt / Equity
0.29
LT Debt / Equity
0.27
-
-
EPS (TTM)
7.14
EPS next Y
-
EPS next Q
-
EPS this Y
-32.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.86%
Revenue last 5Y
14.34%
Revenue Q/Q
-12.59%
EPS Q/Q
15.07%
-
-
-
-
SMA20
4.99%
SMA50
19.14%
SMA100
53.97%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
14%
ROC
0.07%
Gross Margin
47%
Oper. Margin
16%
Profit Margin
10%
Payout
-
Shs Outstand
21.35M
Shs Float
8.29M
-
-
-
-
Target Price
-
52W Range
185.55-419.5
52W High
-9.11%
52W Low
+105.86%
RSI
51.61
Rel Volume
0.05
Avg Volume
40.41K
Volume
1.89K
Perf Week
-2.71%
Perf Month
13.2%
Perf Quarter
47.87%
Perf Half Y
48.28%
-
-
-
-
Beta
0.586
-
-
Volatility
3.82%, 19.69%
Prev Close
1.18%
Price
380.85
Change
2.1%
SAKAR.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 50.24 | 55.46 | 6.28K | 84.92 | 71.73 | |
| Net income per share | 5.16 | 6.43 | 708.58 | 10.05 | 6.86 | |
| Operating cash flow per share | 14.06 | 6.77 | 966.88 | 23.64 | 18.99 | |
| Free cash flow per share | -4.27 | -2.37 | -1.39K | -40.95 | -25.21 | |
| Cash per share | 0.27 | 0.2 | 5.47 | 4.73 | 1.89 | |
| Book value per share | 52.78 | 54.35 | 6.53K | 84.41 | 93.23 | |
| Tangible book value per share | 48.82 | 52.16 | 6.48K | 84.41 | 93.23 | |
| Share holders equity per share | 52.78 | 54.35 | 6.53K | 84.41 | 93.23 | |
| Interest debt per share | 9.86 | 12.57 | 2.98K | 61.72 | 63.03 | |
| Market cap | 733.64M | 851.28M | 8.58M | 859.19M | 3.73B | |
| Enterprise value | 847.51M | 1.02B | 433.73M | 1.79B | 4.84B | |
| P/E ratio | 10.46 | 8.85 | 0.08 | 5.66 | 29.23 | |
| Price to sales ratio | 1.07 | 1.03 | 0.01 | 0.67 | 2.8 | |
| POCF ratio | 3.84 | 8.41 | 0.06 | 2.41 | 10.56 | |
| PFCF ratio | -12.64 | -24.04 | -0.04 | -1.39 | -7.96 | |
| P/B Ratio | 1.02 | 1.05 | 0.01 | 0.67 | 2.15 | |
| PTB ratio | 1.02 | 1.05 | 0.01 | 0.67 | 2.15 | |
| EV to sales | 1.24 | 1.22 | 0.46 | 1.39 | 3.63 | |
| Enterprise value over EBITDA | 4.86 | 4.74 | 1.84 | 6.19 | 12.81 | |
| EV to operating cash flow | 4.44 | 10.03 | 2.98 | 5.01 | 13.71 | |
| EV to free cash flow | -14.6 | -28.67 | -2.07 | -2.89 | -10.33 | |
| Earnings yield | 0.1 | 0.11 | 12.45 | 0.18 | 0.03 | |
| Free cash flow yield | -0.08 | -0.04 | -24.44 | -0.72 | -0.13 | |
| Debt to equity | 0.16 | 0.21 | 0.43 | 0.73 | 0.64 | |
| Debt to assets | 0.12 | 0.15 | 0.24 | 0.35 | 0.33 | |
| Net debt to EBITDA | 0.65 | 0.77 | 1.8 | 3.22 | 2.94 | |
| Current ratio | 1.86 | 1.52 | 1.01 | 1.07 | 1.03 | |
| Interest coverage | 6.69 | 6.44 | 6.48 | 61.64 | 3.21 | |
| Income quality | 1.97 | 0.83 | 1.1 | 1.89 | 2.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.01 | 0 | 0 | 0 | 0.01 | |
| Intangibles to total assets | 0.05 | 0.03 | 0 | 0 | 0 | |
| Capex to operating cash flow | -1.3 | -1.35 | -2.44 | -2.73 | -2.33 | |
| Capex to revenue | -0.36 | -0.16 | -0.38 | -0.76 | -0.62 | |
| Capex to depreciation | -4.12 | -1.93 | -4.41 | -10.09 | -5.48 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 78.28 | 88.69 | 10.2K | 138.18 | 119.98 | |
| ROIC | 0.09 | 0.11 | 0.09 | 0.08 | 0.05 | |
| Return on tangible assets | 0.08 | 0.09 | 0.06 | 0.06 | 0.04 | |
| Graham Net | -6.75 | -14.48 | -4.74K | -69.23 | -81.63 | |
| Working capital | 120.45M | 74.14M | 4.54M | 32.62M | 14.24M | |
| Tangible asset value | 663.25M | 780.4M | 977.22M | 1.27B | 1.73B | |
| Net current asset value | -8.99M | -121.51M | -456.17M | -902.76M | -1.07B | |
| Invested capital | 0.16 | 0.21 | 0.43 | 0.73 | 0.64 | |
| Average receivables | 208.02M | 136M | 42.55M | 143.53M | 143.53M | |
| Average payables | 41.98M | 47.15M | 126.1M | 251.42M | 282.96M | |
| Average inventory | 53.94M | 88.95M | 133.15M | 149.4M | 147.9M | |
| Days sales outstanding | 99.95 | 37.43 | 0 | 81.71 | 0 | |
| Days payables outstanding | 40.8 | 45.34 | 140.21 | 148.82 | 129.47 | |
| Days of inventory on hand | 70.11 | 91.11 | 111.27 | 69.2 | 76.42 | |
| Receivables turnover | 3.65 | 9.75 | 0 | 4.47 | 0 | |
| Payables turnover | 8.95 | 8.05 | 2.6 | 2.45 | 2.82 | |
| Inventory turnover | 5.21 | 4.01 | 3.28 | 5.27 | 4.78 | |
| ROE | 0.1 | 0.12 | 0.11 | 0.12 | 0.07 | |
| Capex per share | -18.33 | -9.13 | -2.36K | -64.59 | -44.21 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 15.95 | 18.01 | 18.79 | 20.04 | 15.75 | |
| Net income per share | 1.01 | 2.16 | 1.81 | 1.46 | 1.68 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 9.96 | 0 | 1.63 | 0 | 0.15 | |
| Book value per share | 80.53 | 0 | 80.12 | 0 | 109.49 | |
| Tangible book value per share | 80.53 | 0 | 80.12 | 0 | 109.49 | |
| Share holders equity per share | 80.53 | 0 | 80.12 | 0 | 109.49 | |
| Interest debt per share | 52.89 | 1.05 | 52.41 | 1.07 | 32.29 | |
| Market cap | 1.1B | 4.17B | 4.34B | 4.99B | 7.37B | |
| Enterprise value | 2.1B | 4.17B | 5.45B | 4.99B | 8.05B | |
| P/E ratio | 14.08 | 25.95 | 27.66 | 43.93 | 50.65 | |
| Price to sales ratio | 3.57 | 12.45 | 10.68 | 12.8 | 21.62 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0.71 | 0 | 2.5 | 0 | 3.11 | |
| PTB ratio | 0.71 | 0 | 2.5 | 0 | 3.11 | |
| EV to sales | 6.85 | 12.45 | 13.41 | 12.8 | 23.61 | |
| Enterprise value over EBITDA | 22.88 | 39.1 | 56.84 | 47.32 | 80.34 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.65 | 0 | 0.64 | 0 | 0.29 | |
| Debt to assets | 0.34 | 0 | 0.33 | 0 | 0.19 | |
| Net debt to EBITDA | 10.96 | 0 | 11.59 | 0 | 6.8 | |
| Current ratio | 1.21 | 0 | 1.03 | 0 | 1.23 | |
| Interest coverage | 5.47 | 3.37 | 2.8 | 2.17 | 3.52 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 42.78 | 0 | 57.17 | 0 | 64.33 | |
| ROIC | 0.01 | 0 | 0.02 | 0 | 0.02 | |
| Return on tangible assets | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Graham Net | -57.6 | 0 | -70.15 | 0 | -43.35 | |
| Working capital | 97.49M | 191.77M | 14.24M | 35.23M | 106.46M | |
| Tangible asset value | 1.55B | 0 | 1.73B | 0 | 2.37B | |
| Net current asset value | -871.52M | 191.77M | -1.07B | 35.23M | -629.82M | |
| Invested capital | 0.65 | 0 | 0.64 | 0 | 0.29 | |
| Average receivables | 43M | 43M | 0 | 0 | 100.74M | |
| Average payables | 64.37M | 64.37M | 130.44M | 130.44M | 89.38M | |
| Average inventory | 59.81M | 59.81M | 76.99M | 76.99M | 111.67M | |
| Days sales outstanding | 25.2 | 0 | 0 | 0 | 53.21 | |
| Days payables outstanding | 67.89 | 0 | 104.48 | 0 | 95.4 | |
| Days of inventory on hand | 63.07 | 0 | 61.66 | 0 | 119.19 | |
| Receivables turnover | 3.57 | 0 | 0 | 0 | 1.69 | |
| Payables turnover | 1.33 | 0 | 0.86 | 0 | 0.94 | |
| Inventory turnover | 1.43 | 0 | 1.46 | 0 | 0.76 | |
| ROE | 0.01 | 0 | 0.02 | 0 | 0.02 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SAKAR.NS Frequently Asked Questions
What is Sakar Healthcare Limited stock symbol ?
Sakar Healthcare Limited is a IN stock and trading under the symbol SAKAR.NS
What is Sakar Healthcare Limited stock quote today ?
Sakar Healthcare Limited stock price is $380.85 today.
Is Sakar Healthcare Limited stock public?
Yes, Sakar Healthcare Limited is a publicly traded company.
Company Profile
- Volume Average 40.41K
- Market Capitalization 8.04B
- Employee 297
- CEO Mr. Sanjay Surendra Shah
- Headquarters Ahmedabad,IN
- IPO Date 2017-03-16
-
Website
https://www.sakarhealthcare.com 
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
